Although Bayer Healthcare, headquartered in Leverkusen, Germany, spent most of 2006 in the spotlight because of its €16.3 billion ($19.6 billion) acquisition of Berlin-based Schering, its ongoing restructuring is bound to yield a total of three new German spin-offs to the ranks of Europe's independent life sciences companies.
This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Related links
Rights and permissions
About this article
Cite this article
Sheridan, C. European pharma consolidation generates quality spinoffs. Nat Biotechnol 24, 1458–1459 (2006). https://doi.org/10.1038/nbt1206-1458
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1206-1458
- Springer Nature America, Inc.